InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,346.99
(
-0.11%
)
US TECH 100
18,488.00
(
-0.25%
)
Dow Jones
38,798.99
(
-0.22%
)
Brent Oil
79.40
(
0.00%
)
Bitcoin
69,400.26
(
0.10%
)
Post# of 252107
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119787
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 114271

Monday, 02/07/2011 11:56:37 PM

Monday, February 07, 2011 11:56:37 PM

Post# of 252107

AZN—ENTHUSE Study 33 is a trial using zibotentan in combination with standard chemotherapy in a more advanced metastatic CRPC setting. This trial will continue and full results are expected in the second half of 2011.

Zibotentan might work in this Taxotere combo trial, which includes patients with advanced bone mets; however, given the two phase-3 failures in earlier-stage CRPC, it’s a very long longshot, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up